Monoclonal antibodies: Technology around the clock for new therapeutic hopes;Anticorps monoclonaux : tours et détours technologiques pour de nouveaux espoirs thérapeutiques

Comptes Rendus - Biologies

Volumn 329, Issue 4, 2006, Pages 217-227

  Bourel, Dominique ^a   Teillaud, Jean Luc ^b  

^a Laboratoire français du fractionnement et des biotechnologies   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

Antibody optimization; Antibody production; Chimeric antibody; Fc receptor; Humanized antibody; Monoclonal antibody; Phage display

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; ANTHRACYCLINE; BASILIXIMAB; BEVACIZUMAB; CETUXIMAB; DACLIZUMAB; EDRECOLOMAB; FC RECEPTOR; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB; MONOCLONAL ANTIBODY; OKT 3; OKT 4; OMALIZUMAB; PALIVIZUMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB;

ANTIBODY; DISEASE; DRUG;

ALLERGIC ASTHMA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BIOENGINEERING; BIOTECHNOLOGY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; COMBINED IMMUNODEFICIENCY; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; DRUG MANUFACTURE; DRUG PURIFICATION; HUMAN; IMMUNOPATHOLOGY; INFECTION; INFLAMMATION; LYMPHOMA; NONHUMAN; ONCOLOGY; SHORT SURVEY; TRANSPLANTATION; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; GENETIC ENGINEERING; HUMANS; TECHNOLOGY;

EID: 33646474866     PISSN: 16310691     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crvi.2006.02.006     Document Type: Short Survey

References (43)

1. Köhler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
2. Hulett M.D., and Hogarth P.M. Molecular basis of Fc receptor function. Adv. Immunol. 57 (1994) 1-127
3. Aguila H., Pollock R.R., Spira G., and Scharff M.D. The production of more useful monoclonal antibodies. II. The use of somatic-cell genetic and recombinant DNA technology to tailor-make monoclonal antibodies. Immunol. Today 7 (1986) 380-383
4. Teillaud J.-L., Desaymard C., Giusti A.M., Haseltine B., Pollock R.R., Yelton D.E., Zack D.J., and Scharff M.D. Monoclonal antibodies reveal the structural basis of antibody diversity. Science 222 (1984) 721-726
5. Spira G., Bargellesi A., Teillaud J.-L., and Scharff M.D. The identification of monoclonal class switch variants by Sib Selection and an ELISA assay. J. Immunol. Methods 74 (1984) 307-315
6. Cumbers S.J., Williams G.T., Davies S.L., Grenfell R.L., Takeda S., Batista F.D., Sale J.E., and Neuberger M.S. Generation and iterative affinity maturation of antibodies in using hypermutating B-cell lines. Nat. Biotechnol. 20 (2002) 1129-1134
7. Olsson L., and Kaplan H.S. Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity. Proc. Natl Acad. Sci. USA 77 (1980) 5429-5431
8. Steinitz M., Klein G., Koskimies S., and Makela O. EB virus induced B lymphocyte cell lines producing specific antibodies. Nature 269 (1977) 420-422
9. Kozbor D., Lagarde A., and Roder J.-C. Human hybridomas constructed with antigen-specific Epstein-Barr virus-transformed cell lines. Proc. Natl Acad. Sci. USA 79 (1982) 6651-6655
10. Carroll W.L., Thielemans K., Dilley J., and Levy R. Mouse × human hetero-hybridomas as fusion partners with human B cell tumors. J. Immunol. Methods 89 (1986) 61-72
11. Karpas A., Dremucheva A., and Czepulkowski B.H. A human myeloma cell line suitable for the generation of human monoclonal antibodies. Proc. Natl Acad. Sci. USA 98 (2001) 1799-1804
12. Borrebaeck C.A., and Möller S.A. In vitro immunization. Effect of growth and differentiation factors on antigen-specific cell activation and production of monoclonal antibodies to autologous antigens and immunogens. J. Immunol. 136 (1986) 3710-3715
13. Banchereau J., de Paoli P., Valle A., Garcia E., and Rousset F. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science 251 (1989) 70-72
14. Traggiai E., Becker S., Subbarao K., Kolesnikova L., Uematsu Y., Gismondo M.R., Murphy B.R., Rappuoli R., and Lanzavecchia A. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 8 (2004) 871-875
15. Traggiai E., Chicha L., Mazzucchelli L., Bronz L., Piffaretti J.C., Lanzavecchia A., and Manz M.G. Development of a human adaptative immune system in cord blood cell-transplanted mice. Science 304 (2004) 104-107
16. Morrison S.L., Johnson M.J., Herzenberg L.A., and Oi V.T. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl Acad. Sci. USA 81 (1984) 6851-6855
17. Torres M., May R., Scharff M.D., and Casadevall A. Variable-region identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype. J. Immunol. 174 (2005) 2132-2142
18. Queen C., Schneider W.P., Selick H.E., Payne P.W., Landolfi N.F., Duncan J.F., Avdalovic N.M., Levitt M., Junghans R.P., and Waldmann T.A. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl Acad. Sci. USA 86 (1989) 10029-10035
19. Roguska M.A., Pedersen J.T., Keddy C.A., Henry A.H., Searle S.J., Lambert J.M., Goldmacher V.S., Blattler W.A., Rees A.R., and Guild B.C. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc. Natl Acad. Sci. USA 91 (1994) 969-973
20. Huse W.D., Sastry L., Iverson S.A., Kang A.S., Alting M.M., Burton D.R., Benkovic S.J., and Lerner R.A. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 246 (1989) 1275-1281
21. Smitth G.P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228 (1985) 1315-1317
22. Huston J.S., Levinson D., Mudgett-Hunter M., Tai M.S., Novotny J., Margolies M.N., Ridge R.J., Bruccoleri R.E., Haber E., Crea R., et al. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl Acad. Sci. USA 85 (1988) 5879-5883
23. Skerra A., and Plückthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 240 (1988) 1038-1041
24. Vaughan T.J., Williams A.J., Pritchard K., Osbourn J.K., Pope A.R., Earnshaw J.C., McCafferty J., Hodits R.A., Wilton J., and Johnson K.S. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotechnol. 14 (1996) 309-314
25. Hoogenboom H.R., and Winter G. By-passing immunisation: human antibodies from synthetic repertoires of germline VH genes segments rearranged in vitro. J. Mol. Biol. 227 (1992) 381-388
26. Geoffroy F., Sodoyer R., and Aujame L. A new phage display system to construct multicombinatorial libraries of very large antibody repertoires. Gene 151 (1994) 109-113
27. Hoogenboom H.R. Overview of antibody phage-display technology and its applications. Methods Mol. Biol. 178 (2002) 1-37
28. Hanes J., Schaffitzel C., Knappik A., and Plückthun A. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat. Biotechnol. 18 (2000) 1287-1292
29. Boder E.T., and Wittrup K.D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15 (1997) 553-558
30. Feldhaus M.J., Siegel R.W., Opresko L.K., Coleman J.R., Feldhaus J.M., Yeung Y.A., Cochran J.R., Heinzelman P., Colby D., Swers J., Graff C., Wiley H.S., and Wittrup K.D. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat. Biotechnol. 21 (2003) 163-170
31. Lonberg N., Taylor L.D., Harding F.A., Trounstine M., Higgins K.M., Schramm S.R., Kuo C.C., Mashayekh R., Wymore K., McCabe J.G., et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368 (1994) 856-859
32. Green L.L., Hardy M.C., Maynard-Currie C.E., Tsuda H., Louie D.M., Mendez M.J., Abderrahim H., Noguchi M., Smith D.H., Zeng Y., et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat. Genet. 7 (1994) 13-21
33. Tomizuka K., Shinohara T., Yoshida H., Uejima H., Ohguma A., Tanaka S., Sato K., Oshimura M., and Ishida I. Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies. Proc. Natl Acad. Sci. USA 97 (2000) 722-727
34. ras promotes tumor regression. Cancer Res. 58 (1998) 1170-1176
35. Caron de Fromentel C., Gruel N., Venot C., Debussche L., Conseiller E., Dureuil C., Teillaud J.-L., Tocqué B., and Bracco L. Restoration of transcriptional activity of p53 mutants in human tumor cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene 18 (1999) 551-557
36. Michon J., Moutel S., Barbet J., Romet-Lemonne J.-L., Deo Y.M., Fridman W.H., and Teillaud J.-L. In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-FcγRI bispecific antibody. Blood 86 (1995) 1124-1130
37. Teeling J.L., French R.R., Cragg M.S., van den Brakel J., Pluyter M., Huang H., Chan C., Parren P.W., Hack C.E., Dechant M., Valerius T., van de Winkel J.G., and Glennie M.J. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104 (2005) 1793-1800
38. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., Xie D., Lai J., Stadlen A., Li B., Fox J.A., and Presta L.G. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J. Biol. Chem. 276 (2001) 6591-6604
39. Umana P., Jean-Mairet J., Moudry R., Amstutz H., and Bailey J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17 (1999) 176-180
40. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., Uchida K., Anazawa H., Satoh M., Yamasaki M., Hanai N., and Shitara K. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278 (2003) 3466-3473
41. Sibéril S., de Romeuf C., Bihoreau N., Fernandez N., Meterreau J.-L., Regenman A., Nony E., Gaucher C., Glacet A., Jorieux S., Klein P., Hogarth M.P., Fridman W.H., Bourel D., Beliard R., and Teillaud J.-L. Selection of a human anti-RhD monoclonal antibody for therapeutic use: Impact of IgG glycosylation on activating and inhibitory FcγR functions. Clin. Immunol. 118 (2006) 170-179
42. Humphreys D.P., and Glover D.J. Therapeutic antibody production technologies: molecules, applications, expression and purification. Curr. Opin. Drug Discov. Devel. 4 (2001) 172-185
43. Roque A.C., Lowe C.R., and Taipa M.A. Antibodies and genetically engineered related molecules: production and purification. Biotechnol. Prog. 20 (2004) 639-654